Anti-coronavirus polypeptides, their derivatives and uses thereof

Polypeptides modified with linkers and cholesterol, targeting the S protein of SARS-CoV-2, effectively inhibit coronavirus variants, addressing the reduced efficacy of existing vaccines and drugs.

JP2024545339AInactive Publication Date: 2024-12-05INST OF MICROBIOLOGY CHINESE ACAD OF SCI +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024538259
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-12-31
Filing Date
2022-03-31
Publication Date
2024-12-05
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current vaccines and monoclonal antibody drugs against SARS-CoV-2 show reduced efficacy against virus variants, necessitating the development of broad-spectrum drugs or vaccines effective against emerging coronavirus strains.

Method used

Development of polypeptides based on the HR2 region of the S protein of SARS-CoV-2, modified with linkers and cholesterol, which inhibit coronavirus infection by interfering with the viral fusion process.

Benefits of technology

The modified polypeptides demonstrate high inhibitory activity against SARS-CoV-2 original and mutant strains, including Alpha, Beta, Gamma, Delta, and Omicron, with enhanced effectiveness against Omicron, suitable for drug or vaccine production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024545339000001_ABST
    Figure 2024545339000001_ABST
Patent Text Reader

Abstract

The present invention relates to anti-coronavirus polypeptides, their derivatives and uses thereof. The present invention provides a polypeptide for anti-coronavirus, and based on this, provides cholesterol-containing derivatives of the above polypeptides. These polypeptide derivatives have unexpected inhibitory effects against coronaviruses, especially the original and mutant strains of SARS-CoV-2, and can be used in the manufacture of drugs or vaccines for the prevention or treatment of the new coronavirus, and have extremely high preventive or therapeutic potential.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the biopharmaceutical field, and in particular to a polypeptide for preventing or treating coronavirus, a derivative thereof, a polynucleotide encoding the polypeptide, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a transformed cell, and a pharmaceutical composition comprising the above, as well as the use of the same in the manufacture of a drug or vaccine for the prevention and / or treatment of the novel coronavirus. [Background technology]

[0002] Coronaviruses are enveloped, linear, single-stranded, positive-sense RNA viruses that are widespread in nature. Some coronaviruses can infect humans and cause disease. To date, there are seven coronaviruses that can infect humans: SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, and HCoV-HKU1.

[0003] SARS-CoV-2 virus is the pathogen of novel coronavirus pneumonia and the third coronavirus causing human epidemics since the 21st century. Currently, various vaccines and monoclonal antibody drugs against SARS-CoV-2 have been approved for emergency use authorization, but many studies have shown that their protective effect against widely circulating novel coronavirus variants such as Beta, Delta, and Omicron is reduced, so there is an urgent need to develop broad-spectrum drugs or vaccines against currently circulating and future emerging novel variants.

[0004] Currently, various COVID-19-related coronaviruses (belonging to sarbecoviruses) have been reported, such as bat-derived RaTG13, RmYN02, ZC45, and ZXC21, and pangolin-derived GX / P2V / 2017 and GD / 1 / 2019. However, research has shown that RaTG13, GX / P2V / 2017, GD / 1 / 2019, etc. can also infect humans. Therefore, there is an urgent need to develop drugs or vaccines against these related coronaviruses to deal with novel epidemics that may emerge in the future. Summary of the Invention

[0005] In view of the shortcomings of the prior art, it is an object of the present invention to provide a polypeptide for the prevention or treatment of coronavirus, a polynucleotide encoding the same, a nucleic acid construct comprising the polynucleotide, an expression vector comprising the nucleic acid construct, a transformed cell, and a pharmaceutical composition comprising the above, as well as their use in the manufacture of a drug or vaccine for the prevention or treatment of coronavirus.

[0006] In a first aspect, the present invention provides a polypeptide for anti-coronavirus, the polypeptide having a sequence as set forth in any one of (1) to (8) below: (1) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, (2) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:2. (3) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:3. (4) A polypeptide comprising the amino acid sequence shown in SEQ ID NO: 12. (5) A polypeptide comprising the amino acid sequence shown in SEQ ID NO: 13. (6) A polypeptide comprising the amino acid sequence shown in SEQ ID NO: 14. (7) A polypeptide comprising an amino acid sequence in which one or more amino acid residues are substituted, deleted, added or inserted in any one of the amino acid sequences of the above polypeptides (1) to (6), and having inhibitory activity against coronaviruses; or (8) A polypeptide comprising an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 93%, 94% or 95% identity to the amino acid sequence of any one of the above polypeptides (1) to (6), and having inhibitory activity against coronavirus.

[0007] Preferably, the sequence of said polypeptide is SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:12, SEQ ID NO:13 or SEQ ID NO:14.

[0008] In a second aspect, the present invention provides a polypeptide derivative for anti-coronavirus, which is the above-mentioned anti-coronavirus polypeptide modified with a cholesterol derivative.

[0009] Furthermore, the modification site of the cholesterol derivative is at the C-terminus, N-terminus, or amino acid base side chain of the polypeptide. Preferably, the modification site of the cholesterol modification is at the C-terminus of the polypeptide.

[0010] Furthermore, the cholesterol derivative is linked to the C-terminus of the polypeptide via a linker or directly.

[0011] Furthermore, the cholesterol derivative is a cholesterol derivative modified with cysteine ​​and / or PEG.

[0012] Furthermore, the cholesterol derivative is JPEG2024545339000002.jpg44128, Selected from JPEG2024545339000003.jpg5376, R2 is OH or NH2; The above n is an integer of 1 to 20, preferably an integer of 2 to 6, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; The above x is an arbitrary integer of 1 to 6, for example, 1, 2, 3, 4, 5, or 6.

[0013] Further, the linker is -NH-PEG-(CH)-CO-, (GSG), (GSGSG), (GSG)-CONH-PEG-(CH)-CO-, or (GSGSG)-CONH-PEG-(CH)-CO-; In the formula, m is an integer from 0 to 6, for example, 0, 1, 2, 3, 4, 5, or 6; The above n is an integer of 1 to 20, preferably an integer of 2 to 6, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20; The above x is an arbitrary integer of 1 to 6, for example, 1, 2, 3, 4, 5, or 6.

[0014] Further, the polypeptide derivatives have the structural formulae shown in Structure I, Structure II, and Structure III below: JPEG2024545339000004.jpg48147Structure IFormula: Polypeptide sequence -R1-Cys(CH2CONH(PEG) n (CH2) x COOChol)-R2 JPEG2024545339000005.jpg54132Structure IIFormula: Polypeptide sequence -R1-Cys(CH2COOChol)-R2 JPEG2024545339000006.jpg47151Structure IIIFormula: Polypeptide sequence-R1-CONH(PEG) n (CH2)x-Cys(CH2COOChol)-R2 Among them, the above polypeptide sequence refers to any one of the above polypeptide sequences (1) to (8), Preferably, the polypeptide sequence is the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:14, The above R1 is (GSG)m or (GSGSG)m, where m is selected from any integer of 0 to 6, and preferably m is 1 or 2; The above R2 is OH or NH2, and preferably R2 is NH2.

[0015] Furthermore, the polypeptide derivatives may be JPEG2024545339000007.jpg35142, JPEG2024545339000008.jpg33144, JPEG2024545339000009.jpg33143, JPEG2024545339000010.jpg32140, JPEG2024545339000011.jpg34145, JPEG2024545339000012.jpg34144, JPEG2024545339000013.jpg38145, JPEG2024545339000014.jpg35141, JPEG2024545339000015.jpg35141, JPEG2024545339000016.jpg36144, JPEG2024545339000017.jpg36143, JPEG2024545339000018.jpg36143, JPEG2024545339000019.jpg36143, JPEG2024545339000020.jpg34142, JPEG2024545339000021.jpg35144, JPEG2024545339000022.jpg35142, JPEG2024545339000023.jpg35145, JPEG2024545339000024.jpg35141, JPEG2024545339000025.jpg42138, JPEG2024545339000026.jpg39138, JPEG2024545339000027.jpg40140, JPEG2024545339000028.jpg40139, JPEG2024545339000029.jpg41139, Selected from JPEG2024545339000030.jpg39134.

[0016] In a third aspect, the present invention provides a polynucleotide sequence for encoding a polypeptide of the first aspect.

[0017] In a fourth aspect, the present invention provides a vector comprising a polynucleotide sequence according to the third aspect.

[0018] In a fifth aspect, the present invention provides a cell comprising a vector according to the fourth aspect of the invention.

[0019] In a sixth aspect, the present invention provides a pharmaceutical composition comprising a polypeptide as provided in the first aspect and / or a derivative as provided in the second aspect and a pharma- ceutically acceptable carrier and / or excipient, In one embodiment, the pharmaceutical composition is in the form of an inhalant, a nasal formulation, or an oral or parenteral formulation; Preferably, the oral formulation is selected from tablets, capsules, granules, suspensions, pills and liquids; Preferably, the parenteral formulation is an injectable or bolus-administrable formulation, More preferably, said pharmaceutical composition is a vaccine composition.

[0020] Preferably, the dosage form of the drug is a tablet, a capsule, a drop, an aerosol, a pill, a powder, a liquid, a suspension, an emulsion, a granule, a liposome, a transdermal agent, a suppository, or a freeze-dried powder injection; Preferably, the drug is administered by injection, such as subcutaneous, intravenous, intramuscular and intraperitoneal injections, intracisternal injection or infusion, intracavity administration, such as rectal, vaginal and sublingual administration, airway administration, such as nasal administration, mucosal administration or surface administration; In a seventh aspect, the present invention provides the use of a polypeptide, polypeptide derivative, fusion protein or complex as described above in the manufacture of a medicament, wherein said medicament is for inhibiting coronavirus or for the treatment and / or prevention of a disease caused by coronavirus.

[0021] Preferably, the coronavirus is selected from the original strains of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or their mutant strains; Preferably, the coronavirus is selected from the SARS-CoV-2 original strain and the SARS-CoV-2 mutant strain.

[0022] More preferably, the SARS-CoV-2 mutant is selected from Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, and Deltacron.

[0023] Preferably, the disease caused by a coronavirus is selected from Corona Virus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome.

[0024] In an eighth aspect, the present invention provides a method for inhibiting coronavirus in vitro comprising using a polypeptide, polypeptide derivative, fusion protein or complex, or pharmaceutical composition as described above, Preferably, the coronavirus is the original SARS-CoV-2 strain and / or a SARS-CoV-2 mutant strain; More preferably, the mutants include Alpha, Beta, Gamma, Delta and Omicron.

[0025] Further, the method of use comprises contacting a polypeptide of the first aspect, a derivative provided in the second aspect and / or a pharmaceutical composition of the third aspect with a virus.

[0026] In a ninth aspect, the present invention provides a method for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, the method comprising administering to the subject a polypeptide, polypeptide derivative, fusion protein or complex, or a pharmaceutical composition as described above, Preferably, the coronavirus is the original SARS-CoV-2 strain and / or a SARS-CoV-2 mutant strain; More preferably, the SARS-CoV-2 mutants include Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, and Deltacron.

[0027] In a tenth aspect, the present invention provides the use of the above polypeptides and polypeptide derivatives, fusion proteins or complexes for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, Preferably, the coronavirus is the original SARS-CoV-2 strain and / or a SARS-CoV-2 mutant strain; More preferably, the mutants include Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, and Deltacron.

[0028] The beneficial effects of the present invention are as follows:

[0029] The present invention designs a polypeptide P3 based on the HR2 region of the S protein of the SARS-CoV-2 virus, and performs a series of modifications thereon (including the addition or substitution of one or more amino acids) to obtain a polypeptide, and then performs linker and cholesterol modifications on the polypeptide to obtain a polypeptide derivative, which has excellent inhibitory effects against the original strain and mutant strains Alpha, Beta, Gamma, Delta and Omicron of SARS-CoV-2, and can be used to manufacture drugs or vaccines for the prevention or treatment of the new coronavirus, and has extremely high preventive or therapeutic potential. [Brief description of the drawings]

[0030] [Figure 1] Inhibitory effect of different polypeptides in Example 2 against pseudovirus of the original strain of SARS-CoV-2. [Diagram 2] Inhibitory effect of different polypeptides in Example 2 against pseudovirus of SARS-CoV-2 mutant strain Omicron. [Diagram 3] The inhibitory effect of polypeptide P3-2 in Example 3 against pseudoviruses of the original novel coronavirus strain and mutant strains Alpha, Beta, Gamma, Delta, and Omicron. [Figure 4] This shows the inhibitory effect of the polypeptide P3-2-GS-Chol in Example 3 against pseudoviruses of the original novel coronavirus strain and mutant strains Alpha, Beta, Gamma, Delta, and Omicron. [Diagram 5] This shows the inhibitory effect of the polypeptide P3-2-PEG-Chol in Example 3 against pseudoviruses of the original novel coronavirus strain and mutant strains Alpha, Beta, Gamma, Delta, and Omicron. [Figure 6]The inhibitory effect of the polypeptide P3-2-GS-PEG-Chol in Example 3 against pseudoviruses of the original novel coronavirus strain and mutant strains Alpha, Beta, Gamma, Delta, and Omicron. [Figure 7] This shows the inhibitory effect of the polypeptide P3-1-GS-PEG-Chol in Example 3 against pseudoviruses of the original novel coronavirus strain and mutant strains Alpha, Beta, Gamma, Delta, and Omicron. [Figure 8] This shows the inhibitory effect of truncated polypeptides P3-2-GS-Chol and P3-2-GS-PEG-Chol in Example 4 after one amino acid is knocked out from the N-terminus, against the pseudovirus of the original strain (SARS-CoV-2 Prototype). [Figure 9] 1 shows the inhibitory effect of truncated polypeptides P3-2-GS-Chol and P3-2-GS-PEG-Chol in Example 4 after one amino acid was knocked out from the N-terminus, against the pseudovirus of mutant Delta. [Figure 10] 1 shows the inhibitory effect of truncated polypeptides in which amino acids of the polypeptides P3-2-GS-Chol and P3-2-GS-PEG-Chol in Example 4 have been knocked out one by one from the N-terminus against the mutant Omicron pseudovirus. [Figure 11] This shows the inhibitory effect of the polypeptide P3-2-GS-chol in Example 5 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero cells. [Figure 12] This shows the inhibitory effect of the polypeptide P3-2-PEG-chol in Example 5 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero cells. [Figure 13] This shows the inhibitory effect of the polypeptide P3-2-GS-PEG-chol in Example 5 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero cells. [Figure 14] This shows the inhibitory effect of the polypeptide P3-2-GS-chol in Example 6 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero E6 cells. [Figure 15] This shows the inhibitory effect of the polypeptide P3-2-PEG-chol in Example 6 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero E6 cells. [Figure 16] This shows the inhibitory effect of the polypeptide P3-2-GS-PEG-chol in Example 6 against live viruses of the original SARS-CoV-2 strain and its mutant strains on Vero E6 cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0031] Coronavirus spike (S) protein plays an important role in the process of mediating viral entry and is divided into two subunits, S1 and S2, among which the S1 subunit is responsible for receptor recognition and the S2 subunit mediates membrane fusion between the viral envelope and the host cell membrane. The heptapeptide repeat sequences HR1 and HR2 in S2 exert their membrane fusion function by forming a six-helix bundle, and studies have suggested that the addition of heterologous HR1 or HR2 polypeptides can inhibit the formation of the six-helix bundle of the virus's own HR1 and HR2, further inhibiting the membrane fusion process.

[0032] The objective of the present invention is to provide a set of polypeptide entry inhibitors that may have inhibitory function against SARS-CoV-2 and SARS-like virus infection, which bind to the HR1 region in the SARS-CoV-2 and SARS-like virus S2 protein and inhibit the viral fusion infection process by interfering with the formation process of the virus' own six-helix bundle.

[0033] The present invention designs polypeptide P3 based on the HR2 region of the S protein of the SARS-CoV-2 virus, and performs a series of modifications thereon (including the addition or substitution of one or more amino acids) to obtain polypeptides P3-1, P3-2, and P3-3, and performs linker and cholesterol modifications on polypeptides P3-1, P3-2, and P3-3 so that the cholesterol-modified polypeptide derivatives have strong inhibitory effects on the original SARS-CoV-2 strain and mutant Omicron strain, and can be used to manufacture drugs or vaccines for the prevention or treatment of the new coronavirus.

[0034] The specific sequences of the polypeptides in the set are as shown in Table 1 or in detail in the Polypeptide Sequence Table. The polypeptides of the invention have inhibitory activity against SARS-CoV-2, and the inhibitory activity of some of the polypeptides reaches an unexpectedly high level, especially, they have achieved excellent inhibitory effect against the novel coronavirus mutant Omicron.

[0035] In the present specification, a polypeptide may be a polypeptide comprising the sequence of any of SEQ ID NOs: 1 to 6 or a mutant thereof.

[0036] For example, a polypeptide may comprise the amino acid sequence shown in SEQ ID NO:1, 2 or 3 in which one or more amino acids have been substituted, added, deleted or inserted.

[0037] Amino acid addition refers to adding an amino acid to the C-terminus or N-terminus of an amino acid sequence, such as the sequence of SEQ ID NO: 1, 2 or 3, as long as the polypeptide has inhibitory activity against coronavirus.

[0038] An amino acid substitution refers to the replacement of an amino acid residue at a certain position in an amino acid sequence, such as the sequence of SEQ ID NO: 1, 2 or 3, with another amino acid residue, so long as the polypeptide has inhibitory activity against coronavirus.

[0039] An amino acid insertion refers to the insertion of an amino acid residue at an appropriate position in an amino acid sequence, e.g., the sequence of SEQ ID NO: 1, 2 or 3, and the inserted amino acid residues may be contiguous to one another in whole or in part, or none of the inserted amino acids are contiguous to one another, so long as the polypeptide has inhibitory activity against coronavirus.

[0040] Amino acid deletion refers to the fact that one, two, three or more amino acids may be removed from an amino acid sequence, such as the sequence of SEQ ID NO: 1, 2 or 3, as long as the polypeptide has inhibitory activity against coronavirus.

[0041] The polypeptide or polypeptide derivative of the present invention may be produced synthetically, or the polypeptide of the present invention may be expressed in a cell. For example, the polypeptide of the present invention may be synthesized by chemical means. Alternatively, the polypeptide of the present invention may be expressed in a recombinant cell. The type of cell is not limited, for example, the cell may be a eukaryotic cell or a prokaryotic cell. The eukaryotic cell may be a fungal cell, such as a yeast cell, or a mammalian cell, such as an insect cell or a mouse cell. The prokaryotic cell may be a bacterial cell, such as an E. coli cell.

[0042] The cholesterol modification of the polypeptide of the present invention can be performed at the C-terminus of the polypeptide, such that the polypeptide is linked to a cholesterol moiety at the C-terminus. The linkage may be direct or via a linker. The method for cholesterol modification of the polypeptide of the present invention is a method known in the prior art.

[0043] The type and length of the linker can vary. For example, the linker can be (GSG)m or (GSGSG)m, where m can be any integer, such as 1, 2, 3, 4, 5, 6, etc.

[0044] The linker may be PEGylated. The means of PEGylation modification are known to those skilled in the art. As used herein, the term PEGylated linker refers to a linker to which one or more PEGs are attached. As used herein, the PEGylated linker may be PEGylated (GSG)n or (GSGSG)n. n may be any integer, such as 1, 2, 3, 4, 5, 6, etc.

[0045] As used herein, "PEGm" means that the number of polyethylene glycol repeating units is m, where m can be any integer, e.g., 1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20.

[0046] As used herein, a coronavirus may be any type of coronavirus. Preferably, the coronavirus is the original strain Prototype or a mutant strain Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, or Deltacron.

[0047] The polypeptide or polypeptide derivative of the present invention can be prepared as a drug or pharmaceutical composition, and such pharmaceutical composition is in the form of an inhalant, a nasal formulation, or an oral or parenteral formulation, Preferably, the oral formulation is selected from tablets, capsules, granules, suspensions, pills and liquids; Preferably, the parenteral formulation is an injectable or bolus-administrable formulation, Preferably, the pharmaceutical composition is a vaccine composition, Such drugs may be in the form of tablets, capsules, drops, aerosols, pills, powders, liquids, suspensions, emulsions, granules, liposomes, transdermal preparations, suppositories, or lyophilized powder injections. These drugs or pharmaceutical compositions may be used by various administration methods, for example, injection administration such as subcutaneous injection, intravenous injection, intramuscular injection and intraperitoneal injection, intracisternal injection or infusion, intracavity administration such as rectal, vaginal and sublingual administration, respiratory administration such as nasal administration, mucosal administration, or surface administration.

[0048] The invention provides a method of preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, comprising administering a polypeptide or polypeptide derivative of the invention.The invention further provides a polypeptide or polypeptide derivative for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject.

[0049] The present invention further relates to a method for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, comprising administering to the subject / patient a composition of a polypeptide or polypeptide derivative of the invention, Preferably, the coronavirus is the original strain Prototype or a mutant strain Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, or Deltacron.

[0050] The present invention further relates to a polypeptide or polypeptide derivative or a composition for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, preferably wherein said coronavirus is the original strain Prototype or a mutant strain Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, Deltacron.

[0051] The present invention further relates to a polypeptide or polypeptide derivative or a composition, pharmaceutical composition, and a reagent kit for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject / patient, preferably wherein said coronavirus is the original strain Prototype or a mutant strain Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, or Deltacron. Working Example

[0052] In order to make the present invention more clearly understood, the present invention will be further described with reference to the following examples and drawings. The examples are merely for the purpose of illustration and are not intended to limit the present invention. In the examples, each raw reagent material is commercially available, and the experimental method without specific conditions is in accordance with the conventional methods and conventional conditions well known in the art, or the conditions recommended by the device manufacturer.

[0053] The present invention will be described in detail below.

[0054] The present invention designs a polypeptide P3 based on the HR2 region of the S protein of SARS-CoV-2, and makes a series of modifications to the P3 polypeptide (including the addition or substitution of one or more amino acids), and names the modified polypeptides P3-1, P3-2, and P3-3, respectively, and performs linker and cholesterol modifications on the polypeptides P3-1, P3-2, and P3-3 to obtain the corresponding polypeptide derivatives, which are directly synthesized by methods commonly used in the art.

[0055] Experimental equipment and materials: Pseudovirus packaging backbone virus G*VSV-delG (purchased from Wuhan PIV Neuroscience and Technology Co., Ltd.).

[0056] Eukaryotic protein pCAGGS expression vector (provided by Suzhou Jinweizhi Co., Ltd.).

[0057] HEK 293T ACE2 cells (provided by Suzhou Jin Weizhi Co., Ltd.).

[0058] Polypeptides: The present inventors designed a polypeptide P3 by comparing the identity of HR1 and HR2 sequences in human infectious coronavirus proteins, and made a series of modifications to the P3 polypeptide (including the addition or substitution of one or more amino acids), named the modified polypeptides P3-1, P3-2, P3-3, respectively, and made a series of linker and cholesterol modifications to the polypeptides P3-1, P3-2, P3-3 to obtain the corresponding polypeptide derivatives, and the specific sequences and structures of these polypeptides and polypeptide derivatives are shown in Table 1. The synthesis and purification were performed by Shenzhen Hanyu Pharmaceutical Co., Ltd., and the purity is >95%.

[0059] [Table 1]

[0060] The pseudoviruses of the original SARS-CoV-2 strain and its mutant strains of the present invention are packaged and obtained in the inventors' laboratory (see Example 2). Example 1

[0061] Packaging of pseudoviruses of the original and mutant strains of SARS-CoV-2 Preparation of expression plasmid for truncated S protein 1) The nucleotides encoding the last 18th amino acid of the S protein of the SARS-CoV-2 original strain (Prototype) and mutant strains (Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (BA.1)) were removed to obtain the nucleotide sequences SARS-CoV-2-Prototype-S-del18, B.1.1.7-S-del18, B.1.351-S-del18, P.1-S-del18, B.1.617.2-S-del18, and BA.1-S-del18, respectively, and were synthesized by Suzhou Jinweizhi Co., Ltd.

[0062] 2) Each nucleotide sequence obtained in 1) was cloned into the pCAGGS expression vector to obtain the expression plasmids pCAGGS-SARS-CoV-2-Prototype-S-del18, pCAGGS-B.1.1.7-S-del18, pCAGGS-B.1.351-S-del18, pCAGGS-P.1-S-del18, pCAGGS-B.1.617.2-S-del18, and pCAGGS-BA.1-S-del18.

[0063] Packaging of pseudoviruses of the original and mutant strains of SARS-CoV-2 a. Cell preparation: HEK 293T cells were seeded onto a 10 cm cell Petri dish so that the cell confluence reached about 80% the next day.

[0064] b. Transfection: The expression plasmid for each S protein obtained in step 2) above was taken and transfected with PEI at 30 μg plasmid / 10 cm cell Petri dish. The target plasmid and PEI were uniformly mixed in a 1:3 ratio before transfection. The culture medium (DMEM medium containing 10% FBS) was replaced every 4 to 6 hours and the cells were cultured at 37°C for 24 hours.

[0065] c. Virus addition: Pseudovirus packaging backbone virus G*VSV-delG (purchased from Wuhan Pivotal Brain Science and Technology Co., Ltd.) was added to the above transfected HEK 293T cells and incubated at 37°C for 2 hours. The culture medium (DMEM medium containing 10% FBS) was then changed, and VSV-G antibody (hybridoma cells expressing the antibody were purchased from ATCC Cell Bank) was added, followed by further incubation in an incubator for 30 hours.

[0066] d. Virus recovery: The supernatant was collected and centrifuged at 3000 rpm for 10 min, filtered through a 0.45 μm sterile filter in an ultra-clean bench to remove cell debris, aliquoted, and stored in a -80°C refrigerator.

[0067] Through the above steps, pseudoviruses of the SARS-CoV-2 original strain (SARS-CoV-2 prototype) and mutant strains (Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (BA.1)) were obtained. Example 2

[0068] Evaluation of the inhibitory effect of polypeptides against the original SARS-CoV-2 strain and its mutant pseudoviruses This example aims to measure the inhibitory effects of the polypeptides in Table 1 against the pseudoviruses of the original strain (SARS-CoV-2 Prototype) and mutant strain Omicron (BA.1).

[0069] Experimental groups: HEK 293T ACE2 cells (blank control group, cells not infected with virus), HEK 293T ACE2 cells + original or mutant pseudovirus + DMEM medium (negative control group, cells infected with virus but not treated with polypeptide), HEK 293T ACE2 cells + original or mutant pseudovirus + polypeptide P3 (P3 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-1 (P3-1 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2 (P3-2 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-3 (P3-3 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-1-GS-Chol (P3-1-GS-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-Chol (P3-2-GS-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-3-GS-Chol (P3-3-GS-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-3-GS2-Chol (P3-3-GS2-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-1-PEG-Chol (P3-1-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-PEG-Chol (P3-2-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-3-PEG-Chol (P3-3-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-1-GS-PEG-Chol (P3-1-GS-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-PEG-Chol (P3-2-GS-PEG-Chol treatment group), HEK 293TACE2 cells + original or mutant pseudovirus + P3-3-GS-PEG-Chol (P3-3-GS-PEG-Chol treatment group).

[0070] Preparation of polypeptide stock solutions: Each polypeptide in Table 1 was first prepared as a 10 mM stock solution in DMSO, and the stock solution was then diluted to 20 μM with DMEM medium containing 10% FBS to serve as a stock solution for further gradient dilutions.

[0071] Preparation of polypeptide gradient dilutions: Each polypeptide stock solution at 20 μM above was diluted 2-fold with DMEM medium containing 10% FBS, for a total of 9 gradient dilutions (10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, 0.156 μM, 0.078 μM, and 0.039 μM, respectively), with 3 parallel wells per gradient and 50 μL per well.

[0072] Determination of pseudovirus dose: Pseudovirus stock and serial dilutions of the SARS-CoV-2 original or mutant strains were quantified on HEK 293T ACE2 cells, and the dilution at which 1,000 FFU appeared was used as the virus dose for evaluating the polypeptide inhibitory effect (dilution ratio was between 6 and 20 times).

[0073] The method for measuring the virus inhibition effect is as follows: a. HEK 293T ACE2 cells were seeded in a 96-well cell culture plate and cultured so that the cell confluence reached 80-90% the next day.

[0074] b. Based on the experimental grouping, each of the polypeptide gradient dilutions was taken and an equal volume (50 μL) of a fixed amount of pseudovirus dilution was added, mixed uniformly, and then incubated at 37° C. for 1 h.

[0075] c. The supernatant of the 96-well cell culture plate in step a was carefully removed, and the polypeptide-pseudovirus mixture in step b (100 μL / well) was added, followed by further culturing in an incubator for 15 to 24 hours.

[0076] d. Count the number of infected cells using a high content microscope, calculate the inhibition rate at different concentrations of each polypeptide, and calculate the EC 50 was calculated (as shown in Figures 1 and 2), and two parallel experiments were performed in total. The results are denoted as 1st and 2nd and are shown in Table 2.

[0077] [Table 2]

[0078] Note: ND is the half effective concentration (EC) at which the polypeptide inhibits the strain within the designed concentration range in this experiment. 50 ) could not be measured.

[0079] Results and Discussion: As can be seen from Table 2, all the polypeptides and their derivatives of the present invention showed an inhibitory effect against coronavirus SARS-CoV-2. Among them, P3-2 has a better inhibitory effect against the original strain Prototype and the mutant strain Omicron than the original P3, but the reproducibility of the inhibition results against the original strain is poor. The inhibitory effects of P3-1-GS-Chol, P3-2-GS-Chol, and P3-3-GS2-Chol against the original strain Prototype and the mutant strain Omicron were significantly superior to those of the corresponding unmodified P3-1, P3-2, and P3-3, respectively. Among them, the inhibitory effect of P3-2-GS-Chol was significantly improved, and the EC 50 The EC values ​​for the two experiments against the mutant strain Omicron were 0.0929 μM and 0.05333 μM, respectively. 50 are 0.02208 μM and 0.01469 μM, respectively; The inhibitory effects of P3-1-PEG-Chol, P3-2-PEG-Chol, and P3-3-PEG-Chol against the original strain Prototype and the mutant strain Omicron were significantly superior to those of the unmodified P3-1, P3-2, and P3-3, respectively. Among them, the inhibitory effect of P3-2-PEG-Chol was significantly improved, and the EC 50 The EC values ​​for the mutant strain Omicron were 0.2113 μM and 0.1955 μM, respectively, and the EC values ​​for the mutant strain Omicron were 0.2113 μM and 0.1955 μM, respectively, 50 are 0.004168 μM and 0.01631 μM, respectively; The inhibitory effects of P3-1-GS-PEG-Chol, P3-2-GS-PEG-Chol, and P3-3-GS-PEG-Chol against the original strain Prototype and the mutant strain Omicron were superior to those of the unmodified P3-1, P3-2, and P3-3, respectively. Among them, the inhibitory effect of P3-2-GS-PEG-Chol was significantly improved, and the EC 50 The EC values ​​for the mutant strain Omicron were 0.1535 μM and 0.0454 μM, respectively, and the EC values ​​for the mutant strain Omicron were 0.1535 μM and 0.0454 μM, respectively, 50 are 0.007021 μM and 0.007624 μM, respectively; Furthermore, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol had the best inhibitory effects against the original strain Prototype and the mutant strain Omicron, with the inhibitory effect against the mutant strain Omicron being particularly pronounced. Furthermore, the P3-2 derivative had good reproducibility between the results of two experiments, suggesting that its inhibitory ability against the virus is the most stable. Example 3

[0080] Evaluation of the inhibitory effect of polypeptide P3-2 and its derivatives against pseudoviruses of the original SARS-CoV-2 strain and its mutant strains This example aims to measure the inhibitory effects of polypeptides P3-2, P3-2-GS-Chol, P3-2-PEG-Chol, P3-2-GS-PEG-Chol, and P3-1-GS-PEG-Chol against pseudoviruses of the original strain (SARS-CoV-2 Prototype) and mutant strains (Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1)).

[0081] Experimental groups: HEK 293T ACE2 cells (blank control group, cells not infected with virus), HEK 293T ACE2 cells + original or mutant pseudovirus + DMEM medium (negative control group, cells infected with virus but not treated with polypeptide), HEK 293T ACE2 cells + original or mutant pseudovirus + polypeptide P3-2 (P3-2 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-Chol (P3-2-GS-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-PEG-Chol (P3-2-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-PEG-Chol (P3-2-GS-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-1-GS-PEG-Chol (P3-1-GS-PEG-Chol treatment group).

[0082] Preparation of polypeptide stock solutions: Each polypeptide in Table 1 was first prepared as a 10 mM stock solution in DMSO, and the stock solution was then diluted to 20 μM in DMEM medium containing 10% FBS to serve as a stock solution for further gradient dilutions.

[0083] Preparation of polypeptide gradient dilutions: Each polypeptide stock solution at 20 μM above was diluted 2-fold with DMEM medium containing 10% FBS, for a total of 9 gradient dilutions (10 μM, 5 μM, 2.5 μM, 1.25 μM, 0.625 μM, 0.3125 μM, 0.156 μM, 0.078 μM, and 0.039 μM, respectively), with 3 parallel wells per gradient and 50 μL per well.

[0084] Determination of pseudovirus dose: Pseudovirus stock and serial dilutions of the SARS-CoV-2 original or mutant strains were quantified on HEK 293T ACE2 cells, and the dilution at which 1,000 FFU appeared was used as the virus dose for evaluating the polypeptide inhibitory effect (dilution ratio was between 6 and 20 times).

[0085] The method for measuring the virus inhibition effect is as follows: a. HEK 293T ACE2 cells were seeded in a 96-well cell culture plate and cultured so that the cell confluence reached 80-90% the next day.

[0086] b. Based on the experimental grouping, each of the polypeptide gradient dilutions was taken and an equal volume (50 μL) of a fixed amount of pseudovirus dilution was added, mixed uniformly, and then incubated at 37° C. for 1 h.

[0087] c. The supernatant of the 96-well cell culture plate in step a was carefully removed, and the polypeptide-pseudovirus mixture in step b (100 μL / well) was added, followed by further culturing in an incubator for 15 to 24 hours.

[0088] d. Count the number of infected cells using a high content microscope, calculate the inhibition rate at different concentrations of each polypeptide, and calculate the EC 50 was calculated (as shown in Figures 3 to 7 ), and the results are shown in Table 3 .

[0089] [Table 3]

[0090] Note: ND is the half effective concentration (EC) at which the polypeptide inhibits the strain within the designed concentration range in this experiment. 50 ) could not be measured.

[0091] Results and Discussion As can be seen from Table 3, the modified derivatives of polypeptide P3-2, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol, not only have excellent inhibitory effects against the original strain Prototype and the mutant strain Omicron of the new coronavirus, but also have excellent data effects against other mutant strains Alpha, Beta, Gamma, and Delta, and the results of the inhibition experiments against the original strain and the mutant strain Omicron are well reproducible. Compared with the derivative P3-1-GS-PEG-Chol of the polypeptide P3-1, the derivatives P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol of the polypeptide P3-2 had better inhibitory effects against the original strain Prototype and the mutant strains Alpha, Beta, Gamma, Delta, and Omicron. Compared with the polypeptide P3-2, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol have better inhibitory effects against the original strain Prototype and the mutant strains Alpha, Beta, Gamma, Delta, and Omicron, among which the inhibitory effect of P3-2-GS-PEG-Chol is superior to that of P3-2-GS-Chol and P3-2-PEG-Chol. For each of the mutant strains Alpha, Beta, Gamma, Delta, and Omicron, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol had the best inhibitory effect against the Omicron strain. Example 4

[0092] Evaluation of the inhibitory effect of the P3-2-GS-PEG-Chol truncated polypeptide and the P3-2-GS-Chol truncated polypeptide against the SARS-CoV-2 original strain and its mutant pseudoviruses This example aims to evaluate the inhibitory effect of truncated polypeptides P3-2-GS-Chol and P3-2-GS-PEG-Chol after the amino acids are knocked out one by one from the N-terminus against pseudoviruses of the original strain (SARS-CoV-2 Prototype) and mutant strains (Delta (B.1.617.2) and Omicron (BA.1)).

[0093] Among them, the amino acid sequences of the truncated polypeptides after one amino acid each of P3-2-GS-Chol and P3-2-GS-PEG-Chol was knocked out from the N-terminus are shown in Tables 4 and 5.

[0094] [Table 4] [Table 5]

[0095] Of these, P3-2-GS-Chol-1 and P3-2-GS-PEG-Chol-1 are extremely unstable during the synthesis and purification processes in production, so they have not been used in experiments to evaluate their inhibitory effects against the original SARS-CoV-2 strain and its mutant pseudoviruses.

[0096] Experimental groups: HEK 293T ACE2 cells (blank control group, cells not infected with virus), HEK 293T ACE2 cells + original or mutant pseudovirus + DMEM medium (negative control group, cells infected with virus but not treated with polypeptide), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-PEG-Chol (P3-2-GS-PEG-Chol treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + polypeptide P3-2-GS-PEG-Chol-2 (P3-2-GS-PEG-Chol-2 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-PEG-Chol-3 (P3-2-GS-PEG-Chol-3 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-Chol-2 (P3-2-GS-Chol-2 treatment group), HEK 293T ACE2 cells + original or mutant pseudovirus + P3-2-GS-Chol-3 (P3-2-GS-Chol-3 treatment group).

[0097] Preparation of polypeptide stock solutions: Each polypeptide in Tables 4 and 5 was first prepared as a 10 mM stock solution in DMSO, and the stock solution was then diluted to 20 μM with DMEM medium containing 10% FBS to prepare a stock solution for further gradient dilutions.

[0098] Preparation of polypeptide gradient dilutions: Each polypeptide stock solution at 20 μM above was diluted three-fold with DMEM medium containing 10% FBS for a total of nine gradients (6.67, 2.22, 0.74, 0.25, 0.082, 0.027, 0.009, 0.003, and 0.001 μM, respectively), with three parallel wells per gradient and 50 μL per well.

[0099] Determination of pseudovirus dose: Pseudovirus stock and serial dilutions of the SARS-CoV-2 original or mutant strains were quantified on HEK 293T ACE2 cells, and the dilution at which 1,000 FFU appeared was used as the virus dose for evaluating the polypeptide inhibitory effect (dilution ratio was between 6 and 20 times).

[0100] The method for measuring the virus inhibition effect is as follows: a. HEK 293T ACE2 cells were seeded in a 96-well cell culture plate and cultured so that the cell confluence reached 80-90% the next day.

[0101] b. Based on the experimental grouping, each of the polypeptide gradient dilutions was taken and an equal volume (50 μL) of a fixed amount of pseudovirus dilution was added, mixed uniformly, and then incubated at 37° C. for 1 h.

[0102] c. The supernatant of the 96-well cell culture plate in step a was carefully removed, and the polypeptide-pseudovirus mixture in step b (100 μL / well) was added, followed by further culturing in an incubator for 15 to 24 hours.

[0103] d. Count the number of infected cells using a high content microscope, calculate the inhibition rate at different concentrations of each polypeptide, and calculate the EC 50 was calculated and the results are shown in Table 6.

[0104] [Table 6]

[0105] Results and Discussion In this example, the truncated polypeptides P3-2-GS-Chol-1 and P3-2-GS-PEG-Chol-1 of P3-2-GS-Chol and P3-2-GS-PEG-Chol were synthesized by solid-phase synthesis. However, these two polypeptides have poor stability and cannot be purified to obtain highly pure samples, and therefore cannot be used to evaluate the inhibitory effect on viruses in a pseudovirus neutralization test.

[0106] As can be seen from Table 6 and Figures 8 to 10, the truncated polypeptides P3-2-GS-PEG-Chol-2 and P3-2-GS-PEG-Chol-3 of the polypeptide P3-2-GS-PEG-Chol also showed better inhibitory effects against the original strain Prototype and the mutant strains Delta and Omicron of the new coronavirus, but the inhibitory effects were all weaker than those of P3-2-GS-PEG-Chol, and such inhibitory effects did not gradually decrease with the gradual truncation of the peptide sequence. The truncated polypeptides P3-2-GS-Chol-2, P3-2-GS-Chol-3, P3-2-GS-Chol-4, and P3-2-GS-Chol-5 of the polypeptide P3-2-GS-Chol also had certain inhibitory effects against the original strain Prototype and the mutant strains Delta and Omicron, but the inhibitory effects were all weaker than those of P-2-GS-Chol.

[0107] Comparing the pseudovirus neutralization test data of the truncated and original-length polypeptides, it was found that the antiviral effects of P3-2-GS-Chol and P3-2-GS-PEG-Chol after cleavage were both reduced to different degrees. Example 5

[0108] Evaluation of the inhibitory effect of derivatives of polypeptide P3-2 against live SARS-CoV-2 original and mutant strains on Vero cells This example aims to measure the inhibitory effect of the polypeptides P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol in Table 1 against live viruses of the original strain (SARS-CoV-2 WH01) and mutant strains Delta (B.1.617.2) and Omicron (BA.1) on Vero cells.

[0109] Experimental groups: Vero cells (blank control group, cells not infected with virus), Vero cells + original or mutant live virus + DMEM medium (negative control group, cells infected with virus but not treated with polypeptide), Vero cells + original or mutant live virus + P3-2-GS-Chol (P3-2-GS-Chol treatment group), Vero cells + original or mutant live virus + P3-2-PEG-Chol (P3-2-PEG-Chol treatment group), Vero cells + original or mutant live virus + P3-2-GS-PEG-Chol (P3-2-GS-PEG-Chol treatment group).

[0110] Preparation of polypeptide stock solutions: The polypeptides P3-2, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol in Table 1 were first prepared as 5 mM stock solutions in DMSO, and then the stock solutions were diluted to 5 μM with DMEM medium containing 2% FBS to serve as stock solutions for further gradient dilutions. The 3-fold doubling dilutions of the polypeptides P3-2-GS-Chol and P3-2-PEG-Chol for the three strains all started from 5 μM, for a total of 11 gradients, the 3-fold doubling dilutions of the polypeptide P3-2-GS-PEG-Chol for the SARS-CoV-2 Prototype and Delta strains started from 5 μM, and the 5-fold doubling dilutions for Omicron started from 5 μM, for a total of 11 gradients, with 4 parallel wells per gradient and 50 μL per well.

[0111] Determination of live virus dose: Calculated by TCID50, SARS-CoV-2 WH01, Delta and Omicron virus solutions were diluted to 2000 TCID50 / mL, respectively, and a total of 9.6 mL was required for each virus solution (prepared based on 12 mL). DMEM (containing 2% FBS) was used for dilution.

[0112] The method for measuring the virus inhibition effect is as follows: a. Based on the experimental grouping, each of the polypeptide gradient dilutions was taken and an equal volume (50 μL) of a fixed amount of live virus dilution was added, mixed uniformly, and then incubated at 37° C. for 1 h.

[0113] b. Suspended Vero cells were added to the mixture and subsequently cultured in an incubator for 48 to 120 hours.

[0114] c. Observe the cell degeneration status, record the number of wells with cell degeneration at 48h, 72h and 120h, respectively, calculate the inhibition rate at different concentrations of each polypeptide, and use GraphPad to calculate the EC 50 was calculated (as shown in Figures 11 to 13) and the results are shown in Table 7.

[0115] [Table 7]

[0116] Results and Discussion As can be seen from Table 7, P3-2-GS-Chol, P3-2-PEG-Chol and P3-2-GS-PEG-Chol have excellent inhibitory effects on the live novel coronavirus on Vero cells.

[0117] In the live virus neutralization test of P3-2-GS-Chol, the CPE (cytopathic effect) was observed and calculated for the original strain of the new coronavirus (WH01) at 48 hours. 50The EC value was 0.5280 μM. For the new coronavirus Delta mutant strain, no CPE was observed in the 48-hour experimental group, at which point the inhibition rate of the polypeptide against the virus was 100%. If the observation time was extended to 72 hours, CPE could be observed. The EC value was calculated to be 0.5280 μM. 50 The EC value was 0.0206 μM. For the novel coronavirus Omicron mutant strain, no CPE was observed in either the 48- or 72-hour experimental groups, at which point the polypeptide's inhibition rate against the virus was 100%. If the observation time was extended to 120 hours, CPE could be observed. The EC value was calculated to be 0.0206 μM. 50 was 0.0362 μM.

[0118] In the live virus neutralization test of P3-2-PEG-Chol, the CPE was observed and calculated for the original strain of the new coronavirus (WH01) at 48 hours. 50 The EC value was 0.5292μM. For the new coronavirus Delta mutant strain, no CPE was observed in the 48-hour experimental group, at which point the inhibition rate of the polypeptide against the virus was 100%. If the observation time was extended to 72 hours, CPE could be observed. The EC value was calculated to be 0.5292μM. 50 The EC value was 0.0206 μM. For the novel coronavirus Omicron mutant strain, no CPE was observed in either the 48- or 72-hour experimental groups, at which point the polypeptide's inhibition rate against the virus was 100%. If the observation time was extended to 120 hours, CPE could be observed. The EC value was calculated to be 0.0206 μM. 50 was 0.1852 μM.

[0119] In the live virus neutralization test of P3-2-GS-PEG-Chol, the CPE was observed and calculated for the original strain of the new coronavirus (WH01) at 48 hours. 50 The EC value was 0.0587μM. For the new coronavirus Delta mutant strain, no CPE was observed in the 48-hour experimental group, at which point the inhibition rate of the polypeptide against the virus was 100%. If the observation time was extended to 72 hours, CPE could be observed. The EC value was calculated to be 0.0587μM. 50The EC value was 0.0406 μM. For the novel coronavirus Omicron mutant strain, no CPE was observed in either the 48- or 72-hour experimental groups, at which point the polypeptide's virus inhibition rate was 100%. If the observation time was extended to 120 hours, CPE could be observed. The EC value was calculated to be 0.0406 μM. 50 was 0.0216 μM.

[0120] Observation time and EC 50 Overall, P3-2-GS-Chol, P3-2-PEG-Chol and P3-2-GS-PEG-Chol were found to be effective against live novel coronavirus on Vero cells, with the best inhibitory effect against Omicron. Example 6

[0121] Evaluation of the inhibitory effect of derivatives of polypeptide P3-2 against live SARS-CoV-2 original and mutant strains on Vero E6 cells This example aims to measure the inhibitory effects of the polypeptides P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol in Table 1 against live viruses of the original strain (SARS-CoV-2 WH01) and mutant strains Delta (B.1.617.2) and Omicron (BA.1) on Vero E6 cells.

[0122] Experimental groups: Vero E6 cells (blank control group, cells not infected with virus), Vero E6 cells + original or mutant live virus + DMEM medium (negative control group, cells infected with virus but not treated with polypeptide), Vero E6 cells + original or mutant live virus + P3-2-GS-Chol (P3-2-GS-Chol treatment group), Vero E6 cells + original or mutant live virus + P3-2-PEG-Chol (P3-2-PEG-Chol treatment group), Vero E6 cells + original or mutant live virus + P3-2-GS-PEG-Chol (P3-2-GS-PEG-Chol treatment group).

[0123] Preparation of polypeptide stock solutions: The polypeptides P3-2, P3-2-GS-Chol, P3-2-PEG-Chol, and P3-2-GS-PEG-Chol in Table 1 were first prepared as 5 mM stock solutions in DMSO, and then the stock solutions were diluted to 5 μM with DMEM medium containing 2% FBS to serve as stock solutions for further gradient dilutions. The 3-fold doubling dilutions of the polypeptides P3-2-GS-Chol and P3-2-PEG-Chol for the three strains all started from 5 μM, for a total of 11 gradients, the 3-fold doubling dilutions of the polypeptide P3-2-GS-PEG-Chol for the SARS-CoV-2 Prototype and Delta strains started from 5 μM, and the 5-fold doubling dilutions for Omicron started from 5 μM, for a total of 11 gradients, with 4 parallel wells per gradient and 50 μL per well.

[0124] Determination of live virus dose: Calculated by TCID50, SARS-CoV-2 WH01, Delta and Omicron virus solutions were diluted to 2000 TCID50 / mL, respectively, and a total of 9.6 mL was required for each virus solution (prepared based on 12 mL). DMEM (containing 2% FBS) was used for dilution.

[0125] The method for measuring the virus inhibition effect is as follows: a. Based on the experimental grouping, each of the polypeptide gradient dilutions was taken and an equal volume (50 μL) of a fixed amount of live virus dilution was added, mixed uniformly, and then incubated at 37° C. for 1 h.

[0126] b. Suspended Vero E6 cells were added to the mixture and subsequently cultured in an incubator for 48-72 h.

[0127] c. Observe the cell degeneration status, record the number of wells with cell degeneration at 48 h and 72 h, calculate the inhibition rate at different concentrations of each polypeptide, and use GraphPad to calculate the EC 50 was calculated (as shown in Figures 14 to 16) and the results are shown in Table 8.

[0128] [Table 8]

[0129] Note: ND is the half effective concentration (EC) at which the polypeptide inhibits the strain within the designed concentration range in this experiment. 50 ) could not be measured.

[0130] Results and Discussion As can be seen from Table 8, P3-2-GS-Chol, P3-2-PEG-Chol and P3-2-GS-PEG-Chol have excellent inhibitory effects on the live novel coronavirus on Vero E6 cells. The EC 50 Since it is possible to observe the time course of the 48-h period, we mainly compared the data from 48 h.

[0131] In the live virus neutralization test of P3-2-GS-Chol, the original strain of the new coronavirus (WH01) was observed on Vero E6 cells for 48 hours and 72 hours, but no inhibitory effect on the live virus was observed in either case. For the new coronavirus Delta mutant strain, CPE was observed in the 48-hour experimental group, and the EC 50 The EC value was 0.3485 μM. For the novel coronavirus Omicron variant, CPE was observed in the 48-hour experimental group, and the EC 50 was 0.0022 μM.

[0132] In the live virus neutralization test of P3-2-PEG-Chol, the original strain of the new coronavirus (WH01) was observed on Vero E6 cells for 48 hours and 72 hours, but no inhibitory effect on the live virus was observed in either case. For the new coronavirus Delta mutant strain, CPE was observed in the 48-hour experimental group, and the EC 50 The EC value was 0.5292 μM. For the novel coronavirus Omicron variant, CPE was observed in the 48-hour experimental group, and the EC 50was 0.0015 μM.

[0133] In the live virus neutralization test of P3-2-GS-PEG-Chol, CPE was observed in the 48-hour experimental group for the new coronavirus Delta mutant strain on Vero E6 cells, and the EC 50 The EC was 0.1208 μM. For the COVID-19 Delta variant, CPE could be observed in the 48-hour experimental group, and the EC 50 The EC value was 0.0403 μM. For the novel coronavirus Omicron variant, CPE was observed in the 48-hour experimental group, and the EC 50 was 0.000028 μM.

[0134] Observation time and EC 50 Overall, P3-2-GS-Chol and P3-2-PEG-Chol are effective against mutant strains of the new coronavirus live virus on Vero E6, with the strongest inhibitory effect against Omicron. P3-2-GS-PEG-Chol is effective against both the original and mutant strains of the new coronavirus live virus, with the strongest inhibitory effect against Omicron.

[0135] In summary, in the process of SARS-CoV-2 entering host cells, the polypeptide and its derivatives of the present invention inhibit the S protein-mediated membrane fusion process to inhibit viral entry, and are applicable to the prevention or treatment of diseases caused by coronaviruses, especially SARS-CoV-2 original and mutant strains. The polypeptide and its derivatives of the present invention have significant inhibitory effects on SARS-CoV-2 original and mutant strains Alpha, Beta, Gamma, Delta, and Omicron, especially mutant strain Omicron, and have wide potential use value.

[0136] The abbreviations and their English meanings in Examples 1 to 6 above are as shown in Table 9 below.

[0137] [Table 9]

[0138] Obviously, the above examples are merely examples for clear explanation, and do not limit the embodiments. Those skilled in the art can make other changes or modifications based on the above description. It is not necessary or possible to cover all the embodiments in this specification. Any obvious changes or modifications derived therefrom still fall within the protection scope of the present invention.

Claims

1. Anti-coronavirus polypeptides comprising the following (1) to (8): (1) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:1, (2) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:

2. (3) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:

3. (4) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:

12. (5) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:

13. (6) A polypeptide comprising the amino acid sequence shown in SEQ ID NO:

14. (7) A polypeptide comprising an amino acid sequence in which one or more amino acid residues are substituted, deleted, added, or inserted in the amino acid sequence of any one of the polypeptides (1) to (6), and having an inhibitory activity against coronavirus; or (8) A polypeptide comprising an amino acid sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 93%, 94% or 95% identity to the amino acid sequence of any one of the polypeptides (1) to (6), and having inhibitory activity against coronavirus. a polypeptide having a sequence according to any one of Preferably, the sequence of the polypeptide is SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:

14. A polypeptide characterized in that

2. A polypeptide derivative for anti-coronavirus, the polypeptide derivative being an anti-coronavirus polypeptide according to claim 1 modified with a cholesterol derivative; Preferably, the modification site of the cholesterol derivative is at the C-terminus, N-terminus, or amino acid base side chain of the polypeptide, more preferably, the modification site of the cholesterol modification is at the C-terminus of the polypeptide; Preferably, the cholesterol derivative is linked to the C-terminus of the polypeptide via a linker or directly, Preferably, the cholesterol derivative is a cysteine-modified cholesterol derivative, or The cholesterol derivative is a cholesterol derivative modified with cysteine ​​and PEG. A polypeptide derivative comprising:

3. The cholesterol derivative is 、 Selected from The R 2 is OH or NH 2 and The n is an integer of 1 to 20, preferably an integer of 2 to 6, wherein x is an integer of 1 to 6; A polypeptide derivative according to claim 2 .

4. The linker is -NH-PEG-(CH 2 )x-CO-, (GSG)m, (GSGSG)m, (GSG)m-CONH-PEGn-(CH 2 )x-CO-, or (GSGSG)m-CONH-PEGn-(CH 2 ) x-CO-, In the formula, m is an integer from 0 to 6. The n is an integer of 1 to 20, preferably an integer of 2 to 6, wherein x is an integer of 1 to 6; A polypeptide derivative according to claim 2 or 3.

5. The polypeptide derivatives have the structural formulas shown in Structure I, Structure II, and Structure III below: 、 、 、 Among them, the above R 1 is (GSG)m or (GSGSG)m, m being selected from any integer from 0 to 6, preferably m being 0, 1 or 2; The R 2 is OH or NH 2 and preferably, R 2 NH 2 and The polypeptide sequence is a polypeptide sequence according to any one of (1) to (8) in claim 1, Preferably, the polypeptide sequence is the sequence of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:12, SEQ ID NO:13, or SEQ ID NO:

14. A polypeptide derivative according to claim 2 .

6. The polypeptide derivative is selected from: 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 、 Selected from A polypeptide derivative according to claim 2 .

7. A polynucleotide sequence, characterized in that it is used to encode the polypeptide according to claim 1.

8. A vector comprising the polynucleotide sequence of claim 7.

9. A cell comprising the vector according to claim 8.

10. A fusion protein or complex, characterized in that it comprises a polypeptide according to claim 1 and / or a polypeptide derivative according to any one of claims 2 to 5.

11. A pharmaceutical composition comprising a polypeptide according to claim 1, and / or a polypeptide derivative according to any one of claims 2 to 5 or a mixture thereof, and / or a fusion protein or complex according to claim 10, and a pharma- ceutically acceptable carrier and / or excipient, Preferably, the pharmaceutical composition is in the form of an inhalant, a nasal formulation, or an oral or parenteral formulation, Preferably, the oral formulation is selected from tablets, capsules, granules, suspensions, pills and liquids; Preferably, the parenteral formulation is an injectable or bolus-administrable formulation; Preferably, the pharmaceutical composition is a vaccine composition. A pharmaceutical composition comprising:

12. Use of a polypeptide according to claim 1, and / or a polypeptide derivative according to any one of claims 2 to 5 or a mixture thereof, and / or a fusion protein or complex according to claim 10, in the manufacture of a medicament, said medicament being used for the inhibition of coronaviruses or for the treatment and / or prevention of diseases caused by coronaviruses, Preferably, the coronavirus is selected from the original strains of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or their mutant strains; Preferably, the coronavirus is selected from the group consisting of SARS-CoV-2 original strain, SARS-CoV-2 mutant strain; More preferably, the SARS-CoV-2 variant is selected from Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, Deltacron; Preferably, the disease caused by coronavirus is selected from Corona Virus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome; Preferably, the dosage form of the drug is a tablet, a capsule, a drop, an aerosol, a pill, a powder, a liquid, a suspension, an emulsion, a granule, a liposome, a transdermal agent, a suppository, or a freeze-dried powder injection; Preferably, the drug is administered by injection, such as subcutaneous, intravenous, intramuscular and intraperitoneal injections, intracisternal injection or infusion, intracavity administration, such as rectal, vaginal and sublingual administration, airway administration, such as nasal administration, mucosal administration or surface administration. use.

13. A method for inhibiting coronavirus in vitro, comprising administering a polypeptide according to claim 1, and / or a polypeptide derivative according to any one of claims 2 to 5 or a mixture thereof, a fusion protein or complex according to claim 10, and / or a pharmaceutical composition according to claim 11, Preferably, the coronavirus is selected from the original strains of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or their mutant strains; Preferably, the coronavirus is selected from the group consisting of SARS-CoV-2 original strain, SARS-CoV-2 mutant strain; More preferably, the SARS-CoV-2 variant is selected from Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, Deltacron; method.

14. A method for preventing or treating a coronavirus infection or a disease caused by a coronavirus in a subject, comprising administering a polypeptide according to claim 1, and / or a polypeptide derivative according to any one of claims 2 to 5 or a mixture thereof, a fusion protein or complex according to claim 10, and / or a pharmaceutical composition according to claim 11, Preferably, the coronavirus is selected from the original strains of SARS-CoV, MERS-CoV, SARS-CoV-2, HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1 or their mutant strains; Preferably, the coronavirus is selected from the group consisting of SARS-CoV-2 original strain, SARS-CoV-2 mutant strain; More preferably, the SARS-CoV-2 variant is selected from Alpha, Beta, Gamma, Delta, Omicron, Kappa, Lambda, Deltacron; Preferably, the disease caused by coronavirus is selected from Corona Virus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome; method.

Citation Information

Patent Citations

  • Polypeptide for inhibiting novel coronavirus (SARS-COV-2) and application of polypeptide

    CN113264990A

  • Polypeptide, and preparation method therefor and use thereof

    WO2021155733A1